- Home
- ACIU vs NHS Comparison
ACIU vs NHS Comparison
Compare ACIU & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- NHS
- Stock Information
- Founded
- ACIU 2003
- NHS 2003
- Country
- ACIU Switzerland
- NHS United States
- Employees
- ACIU N/A
- NHS N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- NHS Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- NHS Finance
- Exchange
- ACIU Nasdaq
- NHS Nasdaq
- Market Cap
- ACIU 213.3M
- NHS 226.7M
- IPO Year
- ACIU 2016
- NHS N/A
- Fundamental
- Price
- ACIU $3.36
- NHS $7.46
- Analyst Decision
- ACIU Strong Buy
- NHS
- Analyst Count
- ACIU 2
- NHS 0
- Target Price
- ACIU $10.00
- NHS N/A
- AVG Volume (30 Days)
- ACIU 417.2K
- NHS 111.8K
- Earning Date
- ACIU 11-04-2025
- NHS 01-01-0001
- Dividend Yield
- ACIU N/A
- NHS 13.44%
- EPS Growth
- ACIU N/A
- NHS N/A
- EPS
- ACIU N/A
- NHS N/A
- Revenue
- ACIU $5,482,957.00
- NHS N/A
- Revenue This Year
- ACIU N/A
- NHS N/A
- Revenue Next Year
- ACIU $1,022.98
- NHS N/A
- P/E Ratio
- ACIU N/A
- NHS N/A
- Revenue Growth
- ACIU N/A
- NHS N/A
- 52 Week Low
- ACIU $1.43
- NHS $6.95
- 52 Week High
- ACIU $4.00
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- ACIU 53.82
- NHS 52.29
- Support Level
- ACIU $3.20
- NHS $7.14
- Resistance Level
- ACIU $3.70
- NHS $7.50
- Average True Range (ATR)
- ACIU 0.40
- NHS 0.08
- MACD
- ACIU -0.01
- NHS 0.01
- Stochastic Oscillator
- ACIU 53.28
- NHS 67.28
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.